60743-58-0

Usage

Uses

Used in Pharmaceutical Industry:
4-hydroxypraziquantel is used as an anthelmintic agent for treating parasitic infections such as schistosomiasis and tapeworms. It exhibits similar anti-parasitic activity to praziquantel, contributing to the overall efficacy of the drug in eliminating parasites from the body.
Used in Medical Diagnostics:
4-hydroxypraziquantel is studied for its potential use as a biomarker for monitoring praziquantel treatment in patients with parasitic infections. Its presence in the body can indicate the effectiveness of the treatment and help in assessing the response to therapy.
Further research is ongoing to better understand the role and potential therapeutic applications of 4-hydroxypraziquantel, including its potential as a biomarker and its contribution to the anthelmintic effects of praziquantel.

InChI:InChI=1/C19H24N2O3/c22-15-7-5-14(6-8-15)19(24)20-11-17-16-4-2-1-3-13(16)9-10-21(17)18(23)12-20/h1-4,14-15,17,22H,5-12H2

Upstream product

• 55268-74-1 2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one 
• 3685-22-1 4-hydroxycyclohexanecarboxylic acid 
• 3618-03-9 methyl 4-hydroxycyclohexanecarboxylate 
• 58752-87-7 C₉H₁₃ClO₃ 
• 61196-37-0 2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one 

Relevant academic research and scientific papers

A method for synthesizing metabolite pqt (by machine translation)

The invention relates to two kinds of pqt of the synthetic method of metabolic product, belongs to the technical field of medicament, are respectively to pqt and 4 the hydroxy [...] cyclohexane carboxylic acid methyl ester as the raw material, pqt and cyclohexenols -3 the [...] formic acid as the raw material to synthesize the pqt two metabolic product. The advantages of: the invention the first time the two portions metabolic product. And, these two kinds of pqt metabolic product of simple synthesis technology, high purity of the product. (by machine translation)

Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data

Objective: Knowledge about the metabolism of anti-parasitic drugs (APDs) will be helpful in ongoing efforts to optimise dosage recommendations in clinical practise. This study was performed to further identify the cytochrome P450 (CYP) enzymes that metabolise major APDs and evaluate the possibility of predicting in vivo drug clearances from in vitro data. Methods: In vitro systems, rat and human liver microsomes (RLM, HLM) and recombinant cytochrome P450 (rCYP), were used to determine the intrinsic clearance (CLint) and identify responsible CYPs and their relative contribution in the metabolism of 15 commonly used APDs. Results and discussion: CLint determined in RLM and HLM showed low (r2=0.50) but significant (Pint values were scaled to predict in vivo hepatic clearance (CLH) using the 'venous equilibrium model'. The number of compounds with in vivo human CL data after intravenous administration was low (n=8), and the range of CL values covered by these compounds was not appropriate for a reasonable quantitative in vitro-in vivo correlation analysis. Using the CLH predicted from the in vitro data, the compounds could be classified into three different categories: high-clearance drugs (> 70% liver blood flow; amodiaquine, praziquantel, albendazole, thiabendazole), low-clearance drugs (int drug categories. The identified CYPs for some of the drugs provide a basis for how these drugs are expected to behave pharmacokinetically and help in predicting drug-drug interactions in vivo.